Identification of the hypertension drug niflumic acid as a glycine receptor inhibitor

Daishi Ito\(^1\), Yoshinori Kawazoe\(^2\), Ayato Sato\(^3\), Motonari Uesugi\(^4\) & Hiromi Hirata\(^{1,5,*}\)

Glycine is one of the major neurotransmitters in the brainstem and the spinal cord. Glycine binds to and activates glycine receptors (GlyRs), increasing Cl\(^-\) conductance at postsynaptic sites. This glycinergic synaptic transmission contributes to the generation of respiratory rhythm and motor patterns. Strychnine inhibits GlyR by binding to glycine-binding site, while picrotoxin blocks GlyR by binding to the channel pore. We have previously reported that bath application of strychnine to zebrafish embryos causes bilateral muscle contractions in response to tactile stimulation. To explore the drug-mediated inhibition of GlyRs, we screened a chemical library of ~1,000 approved drugs and pharmacologically active molecules by observing touch-evoked response of zebrafish embryos in the presence of drugs. We found that exposure of zebrafish embryos to nifedipine (an inhibitor of voltage-gated calcium channel) or niflumic acid (an inhibitor of cyclooxygenase 2) caused bilateral muscle contractions just like strychnine-treated embryos showed. We then assayed strychnine, picrotoxin, nifedipine, and niflumic acid for concentration-dependent inhibition of glycine-mediated currents of GlyRs in oocytes and calculated IC\(_{50}\)s. The results indicate that all of them concentration-dependently inhibit GlyR in the order of strychnine > picrotoxin > nifedipine > niflumic acid.

Glycine, one of the major neurotransmitters, binds to glycine receptor (GlyR), mediating fast inhibitory synaptic transmission in the brain stem and the spinal cord.\(^{12}\) Inhibitory glycinergic transmission is involved in generating rhythms such as respiration and walking/running. GlyRs are pentameric ligand-gated chloride-permeable channels. Extensive studies of mammalian GlyRs have identified four α subunit genes (GLRA1, GLRA2, GLRA3 and GLRA4) and a single β subunit gene (GLRB) with the GLRA4 being a pseudogene in human.\(^{3-8}\) Since mutations in a gene encoding α1 or β subunit of GlyR causes startle reflex defects, which are often referred to as hyperkplexia in human, the major GlyRs in mammals is composed of α1 and β subunits.\(^{9,10}\) GlyRs have also been studied in zebrafish, a vertebrate model, that offer several advantages such as production of many offspring, fast development, optical transparency during embryogenesis and ease of pharmacological assay. Zebrafish have five α subunit (glra1, glra2, glra3, glra4a and glra4b) and two β subunit (glrba and glrbb) genes.\(^{11}\) The existence of two paralogs of a mammalian gene is not uncommon in zebrafish due to an ancestral gene duplication during fish evolution.\(^{12}\) Both glra1 mutant and glrbb mutant zebrafish showed touch-evoked simultaneous contractions of bilateral muscles, and as a consequence startle reflex just like strychnine-treated zebrafish embryos exhibited.\(^{13,14}\) Thus, the major GlyRs in zebrafish embryos comprise α and β subunits as in mammals.

All α subunits form homopentameric GlyRs activated by glycine and inhibited by strychnine and picrotoxin.\(^{15}\) The β subunits, on the other hand, do not form homomers, while they are incorporated in heteropentameric αβ GlyRs, which is activated by glycine and inhibited by strychnine.\(^{6}\) Regardless of homomeric α GlyRs or heteromeric αβ GlyRs, glycine binds to the extracellular intersubunit sites, where strychnine also binds as a competitive antagonist and blocks gating of the channel.\(^{16}\) Picrotoxin binds to the second transmembrane domain of GlyR and clog the channel pore.\(^{17}\) Interestingly, picrotoxin blocks homomeric α GlyRs at low concentration (~10 μM), while ten folds more picrotoxin is necessary to block heteromeric αβ GlyRs in mammals.\(^{18}\) Collectively, these inhibitors provided striking insights to extend our understanding of GlyR properties. Identification and characterization of new GlyR inhibitors are expected to further improve our knowledge of GlyRs.
To search for new chemical compounds that block GlyRs, we screened a chemical library of ~1,000 approved drugs and pharmacologically active molecules through their ability to cause touch-evoked bilateral muscle contractions in zebrafish embryos. Strychnine served as a positive control. The screening identified nifedipine and niflumic acid as candidates of GlyR inhibitors. We also found that picrotoxin also affects zebrafish behavior when applied at high concentration. Our electrophysiological recordings using Xenopus oocytes revealed that all of the strychnine, picrotoxin, nifedipine and niflumic acids showed concentration-dependent blockade of glycine-gated currents in both homomeric and heteromeric GlyRs. In both human and zebrafish GlyR cases, the half-maximal inhibitory concentration (IC₅₀) was strychnine < picrotoxin < nifedipine < niflumic acid.

### Results

**Bath application of nifedipine or niflumic acid affects tactile response of zebrafish.** We have previously reported that zebrafish embryos swim when touched at 24 and 48 h postfertilization (hpf), whereas strychnine-treated embryos show obvious shrinkage of the body without swimming due to the loss of GlyR-mediated reciprocal inhibition. We assumed that in vivo screening of chemical compounds that cause touch-evoked body shrinkage of zebrafish is a promising way to search for new GlyR inhibitors. To this end, three zebrafish embryos were treated with a drug (10 ~ 100 μM) in a well of 96-well plate at the onset of 24 hpf and then assayed for touch responses at 27 and 48 hpf, when zebrafish embryos show tactile-induced short-distance forward movement and escape swimming, respectively. Among ~1,000 drugs that have some known physiological activities, about 79% of the drugs did not affect tactile response, while 10% caused immotile and 10% killed embryos at both stages in our first screening performed in a blind manner. We found 10 drugs that caused touch-evoked body shrinkage or weird uncoordinated response, the latter with contractions of small amplitude and/or compromised rhythmicity (Table 1). We then purchased these drugs, performed second round of screening at several different concentrations and identified three drugs that caused touch-evoked body shrinkage: strychnine, nifedipine and niflumic acid, which are known as specific GlyR inhibitor, voltage-gated calcium channel inhibitor and cyclooxygenase inhibitor, respectively. Successful identification of strychnine in our assay indicates that our screening works well. Nifedipine was previously suggested as a GlyR inhibitor. Although picrotoxin, the other known GlyR inhibitor, was included in our chemical library, we failed to identify it in our screening.

We then detailed tactile response of zebrafish embryos at 48 hpf for four drugs: strychnine, picrotoxin, nifedipine and niflumic acid. Upon touch at the tail, control (1% DMSO) zebrafish embryos showed escape swimming by rhythmic side-to-side trunk contractions (Fig. 1a; Supplementary video 1). The shape of the notochord was straight during swimming. Embryos treated with 70 μM strychnine looked normal before touch. However, when touched, they initially exhibited bilateral trunk contractions resulting in the shrinkage of the body and eventually recovered to the normal state (Fig. 1b; Supplementary video 2). The shape of the notochord became zigzag due to the abnormal body compression along the anterior–posterior axis. Bath application of embryos with picrotoxin at 5 mM but not at lower concentrations caused shrinkage of the body following tactile stimulation. Their notochord was corrugated during abnormal touch response (Fig. 1c; Supplementary video 3). Embryos treated with nifedipine at 200 μM displayed bilateral muscle contractions, and as a consequence dorsally bent of the body just like strychnine-treated embryos showed (Fig. 1d; Supplementary video 4). The shape of the notochord was distorted during the response. Likewise, exposure of embryos with 500 μM niflumic acid induced touch-evoked shrinkage of the body and zigzag notochord (Fig. 1e; Supplementary video 5). These abnormal touch responses in the presence of either four drugs were indistinguishable from touch-evoked behaviors of zebrafish GlyR α1 and GlyRβb mutants. These results indicate that our in vivo chemical screening using zebrafish embryos was sufficient to identify potential GlyR inhibitors. The order of drug concentration efficient for inducing abnormal touch response was strychnine (70 μM) < nifedipine (200 μM) < niflumic acid (500 μM) < picrotoxin (5 mM).

### Homomeric and heteromeric GlyRs of zebrafish and human origins were formed.

To assess the drug sensitivity of GlyRs, we employed electrophysiology using Xenopus oocytes. We first checked glycine-medi-
ated gating of α1 and β subunits of GlyR of zebrafish and human origins, as these subunits were the major GlyR components in vertebrates. We injected cRNAs encoding zebrafish α1 subunit into oocytes, recorded glycine-dependent currents by two-electrode voltage-clamp and detected a concentration-dependent increase of currents for the calculation of half-maximally activated receptor (EC50) and hill coefficients (Fig. 2a,b). Expression of zebrafish α1 subunit with βb subunit also yielded glycine currents, and the cumulative concentration-curve was slightly right-shifted compared with the homomeric zebrafish α1 GlyR case. Similarly, injection of human α1 subunit only and α1 subunit with β subunit in oocytes generated functional homomeric and heteromeric GlyRs, respectively. These zebrafish and human GlyRs were activated by micromolar amounts of glycine and their EC50s were comparable to those in a previous study (Table 2). Injection of zebrafish βb subunit only or human β subunit only into oocytes did not yield currents (data not shown). These data confirm that zebrafish homomeric α1 and heteromeric α1βb GlyRs, as well as human homomeric α1 and heteromeric α1β GlyRs, were properly formed in oocytes.

Niflumic acid blocked both homomeric and heteromeric zebrafish GlyRs by millimolar amounts. Since niflumic acid-treated zebrafish embryos as well as strychnine-, picrotoxin- and nifedipine-treated embryos exhibited abnormal touch response just like zebrafish GlyR mutants showed, niflumic acid likely affect GlyRs as strychnine, picrotoxin and nifedipine do. To address whether these drugs inhibit GlyR, we applied these drugs at different concentrations along with 200 μM glycine to *Xenopus* oocytes that express zebrafish GlyR α1, recorded currents and calculated IC50 and hill coefficients. In addition to strychnine, picrotoxin and nifedipine, niflumic acid showed concentration-dependent inhibition on homomeric zebrafish α1 GlyRs, suggesting that niflumic acid acts on homomeric α1 GlyRs as an inhibitor (Fig. 3a,b). Similarly, niflumic acid...
Acid and the other three GlyR inhibitors caused concentration-dependent inhibition of heteromeric α1βb GlyRs (Fig. 3c,d). The IC50s and hill coefficients of strychnine, picrotoxin, nifedipine and niflumic acid against homomeric α1 GlyRs were higher than that against heteromeric α1βb GlyRs, indicating that niflumic acid efficiently blocks heteromeric zebrafish GlyRs than homomeric zebrafish GlyRs (Table 3). Although the efficient drug concentrations that induce abnormal touch response in zebrafish embryos was strychnine < nifedipine < niflumic acid < picrotoxin, our electrophysiology suggested the order of IC50s as strychnine < picrotoxin < nifedipine < niflumic acid.

### Table 2. Summary of glycine-dependent gating of homomeric and heteromeric zGlyR and hGlyR. Values represent the mean ± SEM from 10 oocytes each. Where indicated *p < 0.05 reflects difference between homomeric and heteromeric GlyR.

| GlyR       | EC50 (µM)   | Hill coefficient |
|------------|-------------|------------------|
| zGlyR α1   | 112 ± 10    | 2.7 ± 0.1        |
| zGlyR α1 + zGlyRβb | 163 ± 16   | 2.5 ± 0.2        |
| hGlyR α1   | 107 ± 7.1   | 2.9 ± 0.1        |
| hGlyR α1 + hGlyRβb | 121 ± 10.2 | 3.2 ± 0.2        |

### Figure 3. Drug-mediated inhibition of homomeric and heteromeric zebrafish GlyRs. (a) A recording from a zGlyRα1-injected oocyte exposed to 200 µM glycine with increasing amounts of niflumic acid. (b) Cumulative concentration-dependent inhibition of GlyRα1 current by strychnine, picrotoxin, nifedipine and niflumic acid (n = 10 each). (c) A recording from an oocyte, which were injected with zGlyRα1 and zGlyRβb and exposed to 200 µM glycine with increasing amounts of niflumic acid. (d) Cumulative concentration-curves of strychnine, picrotoxin, nifedipine and niflumic acid-mediated inhibition of α1/βb heteromeric zebrafish GlyRs (n = 10 each).

Niflumic acid blocked both homomeric and heteromeric human GlyRs at millimolar amounts. We also investigated whether niflumic acid blocks human GlyRs. Exposure of niflumic acid at different concentrations with 200 µM glycine to *Xenopus* oocytes that express human GlyR α1 revealed that niflumic acid blocked GlyR in a concentration-dependent manner (Fig. 4a,b). Our electrophysiology confirmed that
strychnine, picrotoxin and nifedipine also blocked homomeric human α1 GlyRs. Likewise, niflumic acid and the other three GlyR inhibitors showed concentration-dependent inhibition on heteromeric α1β GlyRs (Fig. 4c,d). The IC50s and hill coefficients of strychnine, nifedipine and niflumic acid were comparable between against homomeric α1 and against heteromeric α1β GlyRs. As reported previously, the IC50 of picrotoxin against heteromeric human α1β GlyRs were significantly higher than that against homomeric human α1 GlyRs18. The order of IC50s was strychnine < picrotoxin < nifedipine < niflumic acid. Taken together, these results indicate that niflumic acid is an inhibitor of GlyR.

Discussion
In this study, we employed chemical screening using zebrafish embryos to search for new GlyR inhibitors. Among ~1,000 approved drugs and pharmacologically active molecules, niflumic acid was identified as a candidate. We then performed Xenopus oocyte physiology and calculated IC50s and hill coefficients of niflumic acid against zebrafish and human GlyRs. Interestingly, the sufficient drug concentrations that induce abnormal touch
response in zebrafish embryos were strychnine < nifedipine < niflumic acid < picrotoxin, the values of IC₅₀ of GlyR was strychnine < picrotoxin < nifedipine < niflumic acid.

**In vivo chemical screening to identify new GlyR inhibitors.** Although many zebrafish-based chemical screenings use transgenic or mutant zebrafish and thus need to select transgene-positive or mutation-carrying embryos/larvae, our screening uses wild-type zebrafish embryos at 48 hpf without any selection, enabling easy sample collection for the screening. In our chemical library, drugs were initially solved in DMSO and eventually diluted to 1/100 in each well of a 96-well plate for treatment. Thus, zebrafish embryos are exposed to drugs in the presence of 1% DMSO. This DMSO concentration facilitates the penetration of drugs into zebrafish body and is harmless. With these advantages, our in vivo drug screening tested ~50 drugs in a week and identified strychnine, nifedipine and niflumic acid as potential GlyR inhibitors. Interestingly, we failed to identify picrotoxin in this screening. But this was reasonable because 5 mM concentration of picrotoxin was necessary for inducing abnormal touch response. Since we succeeded in identifying three GlyR inhibitors from ~1,000 drugs, we will be able to find many novel ones if we expand the screening scale. While inhibition of GlyR impairs glycinergic transmission that results in the body shrinkage in zebrafish embryos, inhibition of glial glycine transporter 1 (GlyT1) causes synaptic accumulation of glycine and thus potentiates inhibitory glycinergic transmission, leading to reduction of touch response. Although sarcosine, which is GlyT1 inhibitor, was not included in our chemical library, if it was, body contractions with small amplitude could be seen.

**Niflumic acid as a GlyR inhibitor.** An anti-inflammation drug niflumic acid blocks cyclooxygenase-2 and is clinically used to reduce joint and muscular pain in rheumatoid. It is also known as a blocker of calcium-activated chloride channels, voltage-gated chloride channels and NMDA receptors and GABA receptors. Here we found that niflumic acid blocks both homomeric and heteromeric human GlyRs. Recent studies have investigated that niflumic acid affects human GlyRs expressed in CHO cells with higher blocking potency in homomeric α2 and α3 GlyRs than in homomeric α1 GlyRs. Our electrophysiology results assayed in *Xenopus* oocytes were consistent with their human GlyR results. Since we could also reveal niflumic acid-sensitivity of zebrafish GlyRs and niflumic acid-induced motor deficits in zebrafish embryos, niflumic acid-mediated GlyR inhibition is assumed to be conserved among vertebrates.

**Effective drug concentration for blocking zebrafish GlyRs in *Xenopus* oocytes and zebrafish embryos.** Our electrophysiology in *Xenopus* oocytes and touch-evoked response in zebrafish embryos revealed the effective concentration of drugs in vitro and in vivo, respectively. In the case of strychnine and picrotoxin, the effective concentrations for GlyR inhibition in zebrafish embryos (strychnine: 70 μM; picrotoxin: 5 mM) were 1,000 folds higher than the IC₅₀ values of GlyRs expressed in *Xenopus* oocytes (strychnine: 70 nM; picrotoxin: 6 μM). This 1,000 fold difference is likely due to the low penetration of drugs through the skin. On the other hand for nifedipine and niflumic acid, the effective concentrations to induce abnormal touch response in zebrafish embryos (nifedipine: 200 μM; niflumic acid: 500 μM) were comparable to IC₅₀s of GlyRs in oocyte physiology (nifedipine: 200 μM; niflumic acid: 400 μM). Since both of these drugs are insoluble to water and thus hydrophobic, they can be highly permeable to the skin.

**Material and methods**

**Reagents.** All chemicals and reagents except for library drugs for chemical screening were purchased from Wako Pure Chemical Industries and Thermo Fisher Scientific and used according to manufactures guidelines.

**Animal care and use.** Zebrafish (*Danio rerio*) were reared and maintained at 28.5 °C under a 14 h light and 10 h dark photoperiod and fed twice a day in accordance with the Animal Care and Use Committee at Aoyama Gakuin University. Larvae were staged according to the established guidelines, and are given as hours post-fertilization. At the ages we examined, sex determination has not yet occurred in zebrafish embryos.

**Drug screening.** Two chemical libraries from Kyoto University and Nagoya University, composed of total ~1,000 bioactive compounds, were used in this study. The 2 μl of chemical compounds (1 ~ 10 mM) dissolved in DMSO were diluted to 200 μl with E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl₂, 0.33 mM MgSO₄) and transferred to 96-well plate. Three zebrafish embryos (24 hpf) were transferred into each well of the plate and incubated in a 28.5 °C incubator. At 27 hpf, three embryos with a small amount of drug solution were transferred to a 90-mm dish containing 15 ml of E3 medium and subjected to touch response using forceps under a dissection microscope Leica MZ16. After this assay, embryos with a small amount of E3 solution were transferred back to the drug solution in 96-well plate and incubated in the 28.5 °C incubator. At 48 hpf, embryos were transferred to a 90-mm dish containing 15 ml of E3 medium again and subjected to the touch response. The positive control for this assay was 70 μM strychnine, and the negative control was 1% DMSO.

**Video recording of zebrafish touch response.** Tactile-evoked zebrafish movements in the presence of control 1% DMSO or drug were video recorded at 48 hpf using a dissection microscope. Touch responses elicited by tactile stimulation delivered to the tail with forceps were captured with a high-speed CCD camera at 200 frames per second (HAS-220, Ditect) as described previously. Embryos were exposed to 70 μM strychnine, 5 mM picrotoxin, 200 μM nifedipine, 500 μM niflumic acid for 30 min before assay.
Electrophysiology. Full-length cDNAs encoding zebrafish GlyR α1 and β and human GlyR α1 and β subunits were used in this study. Capped cRNAs for expression in *Xenopus laevis* oocytes were synthesized from linearized templates using SP6 mMessage mMachine SP6 transcription kit (Thermo Fisher Scientific) as described previously32. Oocytes were injected with five femtomoles of cRNA using a Nanoject II (Drummond Scientific). Oocytes were moved to 48-well plates in Barth’s solution (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 mM HEPES at pH 7.5 with NaOH, supplemented with 50 µg/ml gentamicin and 100 units/ml penicillin/streptomycin) and incubated at 18 °C for 24–48 h prior to recording. Oocyte recording solution (90 mM NaCl, 1 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES at pH 7.5 with NaOH) and drug solutions of seven different concentrations were flown into the oocyte chamber using a BPS-8 solution switcher (ALA Scientific). Borosilicate electrodes had resistances of ~2.0 MΩ when filled with 3 M KCl. Two-electrode voltage clamp recordings were made from oocytes held at -70 mV using pClamp 10.2 to control a GeneClamp 500B amplifier via a Digidata 1440A digitizer (Molecular Devices) as described previously33. Signals were low-pass filtered at 10 Hz, and sampled at 100 Hz. Recordings were analyzed using Clampfit 10.7 (Axon Instruments) and SigmaPlot 11.0 (Systat Software, Inc.). EC50s, IC50s and Hill coefficients were calculated sigmoid standard curve as below:

$$y = \min + \frac{(\max - \min)}{1 + (x/EC_{50})^{Hillslope}}$$

$x$: glycine concentration (EC50) or antagonist concentration (IC50), $y$: normalized current. Statistical significance was assessed using the pair-wise analysis of variance.

Ethics statement. All animal experiments described in this manuscript and guidelines for use of zebrafish have been approved by Animal Care and Use Committee in Aoyama Gakuin University.

Received: 3 March 2020; Accepted: 29 May 2020
Published online: 19 August 2020

References

1. Betz, H. et al. Structure and functions of inhibitory and excitatory glycine receptors. *Ann. N. Y. Acad. Sci.* **686**, 667–676 (1999).
2. Lynch, J. W. Molecular structure and function of the glycine receptor chloride channel. *Physiol. Rev.* **84**, 1051–1095 (2004).
3. Grenningloh, G. et al. The strychnine-binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors. *Nature* **328**, 215–220 (1987).
4. Grenningloh, G. et al. Alpha subunit variants of the human glycine receptor: Primary structures, functional expression and chromosomal localization of the corresponding genes. *EMBO J.* **9**, 771–776 (1990).
5. Grenningloh, G. et al. Cloning and expression of the 58 kDa beta subunit of the inhibitory glycine receptor. *Neuron* **4**, 963–970 (1990).
6. Kuhse, J., Schmieden, V. & Betz, H. Identification and functional expression of a novel ligand binding subunit of the inhibitory glycine receptor. *J. Biol. Chem.* **265**, 22317–22320 (1990).
7. Kuhse, J. et al. Alternative splicing generates two isoforms of the alpha 2 subunit of the inhibitory glycine receptor. *FEBS Lett.* **283**, 73–77 (1991).
8. Akagi, H., Hirai, K. & Hishinuma, F. Cloning of a glycine receptor subtype expressed in rat brain and spinal cord during a specific period of neuronal development. *FEBS Lett.* **281**, 160–166 (1991).
9. Shiang, R. et al. Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. *Nat. Genet.* **5**, 351–358 (1993).
10. Rees, M. I. et al. Hyperekplexia associated with compound heterozygous mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). *Hum. Mol. Genet.* **11**, 853–860 (2002).
11. Hirata, H., Carta, E., Yamanaka, I., Harvey, R. J. & Kuwada, J. Y. Defective glycinergic synaptic transmission in zebrafish motility mutants. *Front. Mol. Neurosci.* **2**, 26 (2010).
12. Amores, A. et al. Zebrafish hox clusters and vertebrate genome evolution. *Science* **282**, 1711–1714 (1998).
13. Hirata, H. et al. Zebrafish bandoneon mutants display behavioral defects due to a mutation in the glycine receptor beta-subunit. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 8345–8350 (2005).
14. Samarut, E. et al. Individual knock out of glycine receptor alpha subunits identifies a specific requirement of glr1 for motor function in zebrafish. *PLoS ONE* **14**, e0216159 (2019).
15. Schmieden, V., Grenningloh, G., Schofield, P. R. & Betz, H. Functional expression in Xenopus oocytes of the strychnine binding 48 kD subunit of the glycine receptor. *EMBO J.* **8**, 695–700 (1989).
16. Du, J., Lü, W., Wu, S., Cheng, Y. & Gouaux, E. Glycine receptor mechanism elucidated by electron cryo-microscopy. *Nature* **526**, 224–229 (2015).
17. Yang, Z., Cromer, B. A., Harvey, R. J., Parker, M. W. & Lynch, J. W. A proposed structural basis for picrotoxinin and picrotin binding in the glycine receptor pore. *J. Neurochem.* **103**, 580–589 (2007).
18. Pribilla, I., Takagi, T., Langosch, D., Bormann, J. & Betz, H. The atypical M2 segment of the beta subunit confers picrotoxinin resistance to inhibitory glycine receptor channels. *EMBO J.* **11**, 4305–4311 (1992).
19. Hirata, H., Ogino, K., Yamada, K., Leacock, S. & Harvey, R. J. Defective escape behavior in DEAH-Box RNA Helicase mutants improved by restoring Glycine receptor expression. *J. Neurosci.* **33**, 14638–14644 (2013).
20. Saint-Amant, L. & Drapeau, P. Time course of the development of motor behaviors in the zebrafish embryo. *J. Neurobiol.* **37**, 622–632 (1998).
21. Chen, X. et al. Dihydropyridine inhibition of the glycine receptor: subunit selectivity and a molecular determinant of inhibition. *Neuropharmacol.* **56**, 318–327 (2009).
22. Low, S. E., Ito, D. & Hirata, H. Characterization of the zebrafish glycine receptor family reveals insights into glycine receptor structure function and stoichiometry. *Front. Mol. Neurosci.* **11**, 286 (2018).
23. Cui, W. W. et al. The zebrafish shocked gene encodes a glycine transporter and is essential for the function of early neural circuits in the CNS. *J. Neurosci.* **25**, 6610–6620 (2005).
24. Tilve, G. H., Lengade, J. K., Bavadekar, A. V. & Nair, K. G. Niflumic acid in the management of rheumatoid and osteoarthritis. *J. Postgrad. Med.* 22, 124–129 (1976).

25. White, M. M. & Aylwin, M. Niflumic and flufenamic acids are potent reversible blockers of Ca2+-activated Cl− channels in Xenopus oocytes. *Mol. Pharmacol.* 37, 720–724 (1990).

26. Liantonio, A. et al. Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium. *Br. J. Pharmacol.* 150, 235–247 (2007).

27. Lerma, J. & Del Rio, R. M. Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation. *Mol. Pharmacol.* 41, 217–222 (1992).

28. Sharonova, I. N. & Dvorzhak, A. Y. Blockade of GABAA receptor channels by niflumic acid prevents agonist dissociation. *Biochem. (Mosc) Suppl. Ser. A Membr. Cell Biol.* 7, 37–44 (2013).

29. Maleeva, G., Petretti, F., Zhorov, B. S. & Bregestovski, P. Voltage-dependent inhibition of glycine receptor channels by niflumic acid. *Front. Mol. Neurosci.* 10, 125 (2017).

30. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. *Dev. Dyn.* 203, 253–310 (1995).

31. Ogino, K. et al. RING finger protein 121 facilitates the degradation and membrane localization of voltage-gated sodium channels. *Proc. Natl. Acad. Sci. USA.* 112, 2859–2864 (2015).

32. Hirata, H. et al. Zebrafish relatively relaxed mutants have a ryanodine receptor defect, show slow swimming and provide a model of multi-minicore disease. *Development.* 134, 2771–2781 (2007).

33. Ogino, K. et al. Phosphorylation of gephyrin in zebrafish mauthner cells governs glycine receptor clustering and behavioral desensitization to sound. *J. Neurosci.* 39, 8988–8997 (2019).

Acknowledgements
We thank Hirata Lab members for fish care. We also thank Drs. Sean Eric Low (deceased May 9th, 2018) and Masashi Miyano (Aoyama Gakuin University) for initial technical support of *Xenopus* oocyte physiology and helpful discussion, respectively. This work was supported by Grant-in-Aid for Scientific Research (16H04657, 19H03329, 19H00922) and Scientific Research on Innovative Areas (17H05578) from the MEXT, Japan, the Naito Foundation, the Takeda Science Foundation and the Japan Epilepsy Research Foundation.

Author contributions
D.I. and H.H. designed research; D.I. performed the research and analyzed data; Y.K., A.S. and M.U. provided essential reagents. D.I. and H.H. wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-70983-2.

Correspondence and requests for materials should be addressed to H.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020